Merck (MRK) is no longer in discussions to acquire Revolution Medicines (RVMD), Lauren Thomas and Jonathan Rockoff of Wall Street Journal report, citing people familiar with the matter. The talks “cooled after the two couldn’t come to an agreement on price,” sources told the paper. The talks could restart or another suitor for Revolution could emerge, adds the Journal.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines price target raised to $170 from $85 at Stifel
- Revolution Medicines price target raised to $140 from $77 at RBC Capital
- Revolution Medicines price target raised to $160 from $92 at Guggenheim
- Private Markets: SpaceX interviews banks to lead IPO, Skild AI raises $1.4B
- Expanding RAS-Targeted Franchise and Late-Stage Pipeline Drive Buy Rating on Revolution Medicines